ライフサイエンスコーパス: daily dose

1 suicidality using a gradual titration (1-mg daily dose).

2 ring range, 0 to -2) or reaching the maximum daily dose.

3 uration of use, cumulative dose, and average daily dose.

4 contributing a majority of children's total daily dose.

5 duration, language, and levodopa equivalent daily dose.

6 tcome, with a linear benefit up to the 50-mg daily dose.

7 uration of use, cumulative dose, and average daily dose.

8 PC that is administered as a convenient once-daily dose.

9 uration of use, cumulative dose, and average daily dose.

10 0, or 60mg/kg/day or placebo, divided into 2 daily doses.

11 tively poor BBOX inhibitor and requires high daily doses.

12 oup (P=0.0009) took the prescribed number of daily doses.

13 ral solithromycin or moxifloxacin for 7 once-daily doses.

14 ieves stable plasma concentrations with once-daily dosing.

15 MSM was achieved by approximately 1 week of daily dosing.

16 uration of action in vivo, suitable for once-daily dosing.

17 n in asymptomatic carriers during 8 weeks of daily dosing.

18 less with once-daily dosing than with twice-daily dosing.

19 discovered, with the hopes of achieving once-daily dosing.

20 formulation of tacrolimus designed for once-daily dosing.

21 timated human half-life consistent with once daily dosing.

22 hrombocythemia (ET) can be reversed by twice daily dosing.

23 ecutive d/wk for 3 weeks; and (C) continuous daily dosing.

24 ady state was achieved following 3-4 days of daily dosing.

25 efficacy and safety of bosutinib 500 mg once-daily dosing.

26 d by efficacy, safety concerns, and multiple daily dosing.

27 tic (PK) profile that was predictive of once-daily dosing.

28 (in grams and daily observed doses [defined daily doses]).

29 , 0.57 (95% CI, 0.31 to 1.03) with the 25-mg daily dose, 0.13 (95% CI, 0.04 to 0.38) with the 75-mg d

30 e interval [CI], 0.65 to 1.87) with the 5-mg daily dose, 0.57 (95% CI, 0.31 to 1.03) with the 25-mg d

31 4 [1.33-2.82]), a higher levodopa equivalent daily dose (1.63 [1.09-2.43]), and more frequent exposur

32 ase in rate ratio per 365 additional defined daily doses = 1.06, 95% confidence interval: 0.89, 1.27)

33 ssigned to the celecoxib group (mean [+/-SD] daily dose, 209+/-37 mg), the naproxen group (852+/-103

34 n were randomly assigned to receive a single daily dose (5 mg for 6 weeks, 10 mg for 18 weeks) of don

35 After 8 times daily dosing, 5 of 6 vitreous samples (cohort IV) had un

36 4-10.4) ng/mL (P<0.0001), despite 60% higher daily doses, 8 (5-10) mg vs. 5 (4-7) mg (P<0.0001).

37 A 6-day regimen of nabiximols (maximum daily dose, 86.4 mg of Delta9-tetrahydrocannabinol and 8

38 pared with 91.8% of patients receiving twice-daily dosing (95% confidence interval for twice daily -

39 e patients had an increase of 50 mg to their daily dose across pregnancy.

40 However, daily dosing activated atrophic pathways, including F-bo

41 showed anxiolytic-like signatures following daily dose administration (50 mg/kg, ip) for 13 days.

42 Chronic steroid use usually involves once-daily dosing, although weekly dosing in children has bee

43 tes increased significantly with the average daily dose among youths with more than 150 days of SSRI

44 During and following treatment, the daily dose and blood level of tacrolimus remained stable

45 The risk of toxicity is dependent on daily dose and duration of use.

46 ere were no significant associations between daily dose and either all-cause or noncardiac mortality.

47 In view of its once-daily dose and favourable safety profile, WTX101 could i

48 We analyzed the combined factors of daily dose and lipophilicity for 164 US Food and Drug Ad

49 The median (interquartile range) daily dose and trough concentration at time of nephrotox

50 ombinations (FDC) with the advantage of once daily dosing and improved tolerability and toxicity prof

51 bioavailability of LCP-Tacro allows for once-daily dosing and similar (AUC) exposure at a dose approx

52 However, daily dosing and split dosing might increase serum hepci

53 t demonstrated properties indicative of once-daily dosing and superior potency against resistant vira

54 Ten women were assigned to receive once-daily dosing and ten were assigned to receive twice-dail

55 , 0.13 (95% CI, 0.04 to 0.38) with the 75-mg daily dose, and 0.32 (95% CI, 0.17 to 0.59) with the 400

56 chemical structure, molecular weight, total daily dose, and complexity of synthesis.

57 confidence interval [CI], 69%-100%) after 5 daily doses, and remained >90% for 7 days after stopping

58 lerated, had a PK profile supportive of once-daily dosing, and produced a rapid and substantial decre

59 s (intermittent arm); cohort B, 80 mg daily (daily dosing arm).

60 Phases 2 and 3 showed that daily dosing at 3.5-6 g resulted in a sustained and sign

61 0752, 21 patients received a continuous once-daily dosing at 450 and 600 mg; 17 were dosed on an inte

62 ment of chronic non-cancer pain with a total daily dose averaging at least 30 mg (morphine equivalent

63 ties could lead to an underestimation of the daily dose by a factor of 0.08-1.78.

64 ransgenic mice to greater than 90% with once-daily dosing by inhalation.

65 ntermittent schedule as well as a continuous daily dosing (CDD) schedule.

66 sers, defined as having a cumulative defined daily dose (cDDD) >/=28, were selected and served as the

67 The cumulative defined daily dose (cDDD), which indicates the exposed duration

68 in use was measured using cumulative defined daily dose (cDDD).

69 to 365, and more than 365 cumulative defined daily doses (cDDDs), respectively, relative to no statin

70 s defined as more than 30 cumulative defined daily doses (cDDDs); PPI nonuse was defined as 30 cDDDs

71 tatins (defined as >/= 28 cumulative defined daily doses [cDDDs]), 1,378 had HCC.

72 over 4 days dosing (cohort III) and 8 times daily dosing (cohorts II and IV) resulted in reliably hi

73 somer was injected into the food source at a daily dosing concentration of 0.239 ng/g kestrel/day (22

74 no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 +/- 1.3 mg/d), Ctrou

75 MRA after diagnosis suggests that a defined daily dose (DDD) of MRA between 12.5 and 50 mg may allev

76 Data on mean cumulative defined daily doses (DDDs) of MRP inhibitors (NSAIDs, PDE5-i, sa

77 easured as World Health Organization defined daily doses (DDDs) per 1000 patient-days.

78 otics fell by 47% (mean decrease 224 defined daily doses [DDDs] per 1000 OBDs, 95% CI 154-305, p=0.00

79 However, higher daily dose did not increase the risk of optic neuropathy

80 was superior to placebo, but the 5 mg twice daily dose did not show non-inferiority to etanercept 50

81 thromboprophylaxis (heparin, enoxaparin once-daily dosing, early ambulation), hospital discharge befo

82 At oral daily dose-equivalent of 3 mg/kg, 12 exhibited analgesic

83 ctions, superior resistance profile and once-daily dosing favours abacavir for African children, supp

84 rtesunate 8 mg/kg/d as a once-daily or twice-daily dose for 3 days, followed by mefloquine.

85 ritoneally at 5 min after TBI, followed by a daily dose for 3-21 d.

86 rtesunate 6 mg/kg/d as a once-daily or twice-daily dose for 7 days, or artesunate 8 mg/kg/d as a once

87 The median average daily dose for all subjects over the course of the study

88 t treatment with nifurtimox (8-10 mg/kg in 3 daily doses for 12 weeks) from March 2008 to July 2012.

89 erine (60 mg/kg) was given orally in divided daily doses for 16 weeks.

90 ptic shock may need relatively high colistin daily doses for efficacy against multidrug-resistant and

91 in the past, with lower pill burden and once-daily dosing frequency common.

92 The 10-year average daily dose from individual and multivitamin supplements

93 vailability and prolonged exposures for once-daily dosing, good colonic absorption and a reliable con

94 IV-1 RNA were similar for the 40-120 mg once-daily dose groups regardless of baseline Gag polymorphis

95 ng-term, high-intensity use (average defined daily dose >/=0.3) of agents with high cyclooxygenase-2

96 RO2) and found lipophilicity (logP >/=3) and daily dose >/=100 mg of oral medications to be associate

97 e rechallenge exhibit multiple risk factors: daily dose >50 mg, an increased incidence of ALT elevati

98 Citalopram daily doses >40 mg were associated with lower risks of v

99 s, the associations were stronger for higher daily doses (>1.5 vs <0.75 PPI pills/d; P value interact

100 At month 6, 90.5% of patients receiving once-daily dosing had maintained clinical remission, compared

101 P = 0.002), especially for users with higher daily doses (HR, 0.54; 95% CI, 0.35-0.83; P = 0.005).

102 The median daily dose in the high-dose group was 9 MIU (interquarti

103 not take at least 16 of 21 prescribed total daily doses in cycle 1 because of toxicities attributabl

104 um hepatic GCS inhibition after four or five daily doses in rodents.

105 st and efficacious at lowering IOP with once daily dosing in a normotensive mouse model.

106 l regimens with once-daily compared to twice-daily dosing in diverse areas of the world.

107 y at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients.

108 LY2562175 were consistent with enabling once daily dosing in humans, and it was ultimately advanced t

109 Use of rifamycins for >/=8 months and daily dosing in the intensive phase also improve TB trea

110 ned that every additional carbapenem defined daily dose increased the hazard of acquiring carbapenem-

111 taken, decreased as the number of prescribed daily doses increased.

112 Detection of toxic daily dosing is a cost-effective way to reduce hydroxych

113 Based on daily dose, lipophilicity, and RM, a DILI score algorith

114 tive metrics, we analyzed the association of daily dose, logP, and formation of reactive metabolites

115 model) defined the relative contribution of daily dose, logP, and RM and permitted a quantitative as

116 wer dosages (40-80 mg Fe) and avoiding twice-daily dosing maximize fractional absorption.

117 cognitive deficits, these data suggest that daily dosing may be critical to allow for development of

118 In this preliminary trial, ozanimod at a daily dose of 1 mg resulted in a slightly higher rate of

119 A daily dose of 1 mg TA-8995 increased HDL cholesterol lev

120 20% of subjects receiving LCI699 at a total daily dose of 1.0 mg.

121 A daily dose of 1.4 g of omega-3 PUFAs or placebo (paraffi

122 -daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg.

123 Daily dose of 100 mg of doxycycline (n = 144) or placebo

124 L/Zi was administrated for 8 weeks at a daily dose of 100 mg/kg BW.

125 centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction

126 tipation were randomly assigned to receive a daily dose of 12.5 or 25 mg of naloxegol or placebo.

127 The antihypertensive efficacy of HCTZ in its daily dose of 12.5 to 25 mg as measured in head-to-head

128 3%) were cured after treatment with a single daily dose of 120 mg/kg BKI-1517.

129 12 weeks of ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, an

130 coformulated ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, an

131 eatment with ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, an

132 rmulation of ABT-450/r-ombitasvir (at a once-daily dose of 150 mg of ABT-450, 100 mg of ritonavir, an

133 ompared with tiotropium HandiHaler at a once-daily dose of 18 mug.

134 A daily dose of 2 g gluten was selected for the interventi

135 nd efficacy of tiotropium Respimat at a once-daily dose of 2.5 mug or 5 mug, as compared with tiotrop

136 r stroke to receive either rivaroxaban (at a daily dose of 20 mg) or dose-adjusted warfarin.

137 dy-surface area) to bardoxolone methyl, at a daily dose of 20 mg, or placebo.

138 findings support the use of topiramate at a daily dose of 200 mg to reduce heavy drinking in problem

139 eatment with topiramate (N=67), at a maximal daily dose of 200 mg, or matching placebo (N=71).

140 tients were given oral ODM-201 at a starting daily dose of 200 mg, which was increased to 400 mg, 600

141 ned 261 patients to receive lenvatinib (at a daily dose of 24 mg per day in 28-day cycles) and 131 pa

142 who received ombitasvir-ABT-450/r (at a once-daily dose of 25 mg of ombitasvir, 150 mg of ABT-450, an

143 ive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose o

144 tial benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously.

145 ment was <40%, even with the maximum allowed daily dose of 360mg colistin base activity.

146 ment was <40%, even with the maximum allowed daily dose of 360mg colistin base activity.

147 esponse to biologic DMARDs, baricitinib at a daily dose of 4 mg was associated with clinical improvem

148 Simvastatin at a daily dose of 40 mg did not affect exacerbation rates or

149 mized, controlled trial of simvastatin (at a daily dose of 40 mg) versus placebo, with annual exacerb

150 of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy

151 Ibrutinib at a daily dose of 420 mg was administered orally until disea

152 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or r

153 iletine therapy was 36 months, at an average daily dose of 8 +/- 0.5 mg/kg.

154 lemental infant formula given enterally in a daily dose of 8.2 to 9.2 log10 CFU; the placebo was dilu

155 s seen by day 8 in most patients receiving a daily dose of 80 mg or higher.

156 ds (ie, two capsules a day providing a total daily dose of 800 mg docosahexaenoic acid and 225 mg eic

157 0 patients who received colistin at a median daily dose of 9 million IU (MIU; interquartile range, 5.

158 The mean (SD) daily dose of amisulpride was 272 (168; range, 50-800) m

159 ch an HIV-negative individual takes a single daily dose of an antiretroviral drug so that, if exposed

160 The benefit of the 5 mg twice daily dose of apixaban (n = 8665) compared with warfarin

161 Similarly, the benefit of 5 mg twice daily dose of apixaban compared with warfarin on major b

162 The 5 mg twice daily dose of apixaban is safe, efficacious, and appropr

163 criteria assigned to receive the 5 mg twice daily dose of apixaban or warfarin, 3966 had 1 dose-redu

164 show consistent benefits with the 5 mg twice daily dose of apixaban vs warfarin compared with patient

165 uction criterion who received the 5 mg twice daily dose of apixaban.

166 nce interval [CI] 2.59-6.63, P < .001) and a daily dose of BAK greater than 3 (OR 2.47, 95% CI 1.17-5

167 kers, topical carbonic anhydrase inhibitors, daily dose of BAK, and glaucoma filtration surgery.

168 A moderate daily dose of both forms of long-chain omega-3 EFAs, for

169 Healthy participants received a daily dose of CETP inhibitor (n=10) or placebo (n=15) fo

170 ociation and statistical interaction of mean daily dose of corticosteroids and intensive care unit le

171 onth follow-up while subjects were on a 10mg daily dose of donepezil or placebo.

172 eceived artesunate, administered orally at a daily dose of either 2 mg per kilogram of body weight pe

173 Rat pups were treated with a daily dose of ethanol (4.5g/kg body weight) delivered by

174 model outcome is a distribution of a child's daily dose of feces via each exposure route.

175 We established the optimal daily dose of gluten to be used in a 6-week challenge st

176 required for oocyte maturation, whereas the daily dose of gonadotropin or the total number of metaph

177 A larger daily dose of inhaled glucocorticoid in the first 2 year

178 Previous phase 1 studies identified a low daily dose of interleukin-2 (IL-2) that was well tolerat

179 Mean daily dose of LCPT was significantly (p < 0.0001) lower

180 cibility of the bronchodilator response to a daily dose of nebulised RPL554 (0.018 mg/kg) for 6 conse

181 Administration of a single daily dose of nicotine has been shown to entrain circadi

182 orts of three to six patients and received a daily dose of ODM-201, 200-1800 mg.

183 Treatment with a 50-mg once-daily dose of opicapone was associated with a significan

184 s directly related to the maximum prescribed daily dose of opioid medication.

185 or greater reduction from baseline in their daily dose of oral calcium and active vitamin D while ma

186 The median daily dose of oral corticosteroids among the 165 patient

187 A 200 mg once daily dose of oral tedizolid phosphate for 6 days or 600

188 f those in the placebo group, had an average daily dose of prednisolone or prednisone of 4.0 mg or le

189 a dose approximately 30% less than the total daily dose of Prograf.

190 feron-alpha2a and lower, conventional 800 mg daily dose of ribavirin.

191 unting for 86.9% of statin use); the defined daily dose of simvastatin was lower in cases than in con

192 d protocol that involved administering a low daily dose of tacrolimus (TAC) to a cohort of 17 patient

193 tective mucosal tissue exposure by the third daily dose of tenofovir disoproxil fumarate plus emtrici

194 -to-severe plaque psoriasis, the 10 mg twice daily dose of tofacitinib was non-inferior to etanercept

195 However, the daily dose of TXA is high due to its modest potency and

196 STN at a daily dose of up to 20 mg/kg was relatively well tolerat

197 by the vasopressor-free days and by the mean daily dose of vasopressor to insure a mean arterial pres

198 ctors independently associated with the mean daily dose of vasopressors.

199 RT, the cumulative dose and the mean daily dose of VGB influenced isopters' area obtained wit

200 ter's area and both cumulative dose and mean daily dose of VGB.

201 50.8 nmol/L) (P < 0.0002)].With the use of a daily dose of vitamin D relevant to public health recomm

202 The mean daily dose of vitamin D was 1275 IU for sufficient patie

203 The rats received daily doses of 0.09% NaCl (control group) or 10 mg/kg bo

204 given via intraperitoneal and oral routes at daily doses of 0.6 and 0.9 mg/kg, the prodrug was also e

205 ratio=0.90, 95% CI=0.86-0.96) compared with daily doses of 1-20 mg.

206 armustine applied once in combination with 2 daily doses of 120 mg/m2 of O6-benzylguanine.

207 y with peginterferon and ribavirin, received daily doses of 150 mg of ABT-450 and 100 mg of ritonavir

208 re given single doses (phase 1) and repeated daily doses of 2-8 g oral nicotinamide for 5 days (phase

209 tions of vehicle, 200 or 300 mg/kg ISO, or 2 daily doses of 200 mg/kg ISO for 6 days.

210 Citalopram daily doses of 21-40 mg were associated with lower risks

211 , patients received oral brigatinib at total daily doses of 30-300 mg (according to a standard 3 + 3

212 Hepatotoxicity was observed in humans at daily doses of 400 mg but was not replicated in any of t

213 asked titration with axitinib to total twice daily doses of 7 mg, and then 10 mg, if tolerated, or pl

214 rin (1000 to 1200 mg per day) and one of two daily doses of ABT-450/r.

215 Mean daily doses of benzodiazepines and opioids were lower in

216 We examined 31 rGBM patients treated with daily doses of cediranib, acquiring serial chemical shif

217 ntrations in healthy subjects receiving oral daily doses of CPP-115 or placebo.

218 treat in silico granulomas with recommended daily doses of each FQ and compare efficacy by multiple

219 26 patients with recent ACS to receive twice-daily doses of either 2.5 mg or 5 mg of rivaroxaban or p

220 ent acute coronary syndrome to receive twice-daily doses of either 2.5 mg or 5 mg of rivaroxaban or p

221 Treatment with eight daily doses of IL-37 resulted in a further 326% increase

222 t using topical carmustine plus 2 subsequent daily doses of intravenous O6-benzylguanine, administere

223 ealth care professional, for 3 months vs 270 daily doses of isoniazid, without supervision by a healt

224 n a chamber model and rodent tumor models at daily doses of less than 3 mg/kg by targeting the tumor

225 interruption was associated with higher mean daily doses of midazolam (102 mg/d vs 82 mg/d; P = .04)

226 ducted to determine the effect of lower once daily doses of OC000459 and to define the phenotype of s

227 Daily doses of OCA, ranging from 10 to 50 mg, significan

228 th CPY17 inhibitors, to receive one of three daily doses of ODM-201 (200 mg, 400 mg, and 1400 mg).

229 e-expansion cohorts assigned to receive once-daily doses of oral gilteritinib (20 mg, 40 mg, 80 mg, 1

230 (once every 5 days) schedule or combining 5 daily doses of POS with 7 intermittent doses of BZ also

231 Higher daily doses of primaquine have the potential to cause cl

232 lent, but 57% of patients took <75% of their daily doses of proguanil.

233 By combining lower once-daily doses of STN (7 or 2 mg/kg) with CsA (20 mg/kg), M

234 o 2.6-fold decrease in tracer uptake after 4 daily doses of sunitinib.

235 After 10 days of treatment, all three daily doses of tropisetron significantly improved overal

236 Both the 5-mg and 10-mg daily doses of ulipristal acetate were noninferior to on

237 and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body weight.

238 Participants received twice-daily doses of vigabatrin (total dosage, 3.0 g/d) or mat

239 Interventions Daily dosing of 800 IU of vitamin E (58 patients), 1000

240 rmacodynamic modelling exercises, that twice daily dosing of artemisinins increases malaria parasite

241 especially in HIV-1-infected women, and once-daily dosing of EFV+FTC-TDF are advantageous for use of

242 cks within strata to receive open-label oral daily dosing of erlotinib (150 mg), cabozantinib (60 mg)

243 Twice daily dosing of GSK2656157 results in dose-dependent inh

244 ed, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be effecti

245 transiently ameliorate hyperglycemia through daily dosing of one or more antidiabetic drugs.

246 -life of 12-48 h is generally ideal for once daily dosing of oral drugs.

247 bility and acceptability of daily versus non-daily dosing of oral HIV pre-exposure prophylaxis (PrEP)

248 formed under maximal acid suppression (twice daily dosing of proton pump inhibitor therapy) in 8-12 w

249 t disease modifying benefits associated with daily dosing of SMT022357, a second-generation compound

250 us, duration of intervention, iron form, and daily dose on the change in iron status in response to i

251 mpact of pill burden and once-daily vs twice-daily dosing on ART adherence and virological outcomes.

252 l ones throughout timepoints either by total daily dose or adjusted (Adj) per body weight.

253 ing (P=0.024) and 93.5% for patients on once-daily dosing (P=0.008).

254 igher serum hepcidin concentration than once-daily dosing (p=0.013).

255 d 84%, compared to 91% for patients on twice-daily dosing (P=0.024) and 93.5% for patients on once-da

256 ps (73% +/- 26% vs 46% +/- 28% of prescribed daily doses; P < .0001), but not between PAD and non-PAD

257 to 0.85) for a dose of 0.01 to 0.75 defined daily dose per day, 0.87 (95% CI, 0.83 to 0.89) for 0.76

258 % CI, 0.83 to 0.89) for 0.76 to 1.50 defined daily dose per day, and 0.87 (95% CI, 0.81 to 0.91) for

259 , 0.81 to 0.91) for higher than 1.50 defined daily dose per day; the corresponding hazard ratios for

260 ed to a reduction in mean antibiotic defined daily doses per 100 patient-days from 101.38 (95% CI 93.

261 n was assessed with the WHO index of defined daily doses per 100 patient-days, and the primary outcom

262 28, p=0.008) and the community (1.85 defined daily doses per 1000 inhabitant-days, 95% CI 0.23-3.48,

263 robial consumption data, measured by Defined daily Doses per 1000 inhabitants per day, from the Europ

264 ntervention (change in level, -216.8 defined daily doses per 1000 OBDs; 95% confidence interval, -347

265 n both hospitals (mean reduction 193 defined daily doses per 1000 occupied bed-days, 95% CI 45-328, p

266 on cost-savings, ease, and convenience of a daily-dosing pill.

267 Cumulative glucocorticoid doses (daily dose plus methylprednisolone pulse) during the fir

268 of use (Ptrend = .036) and higher prescribed daily dose (Ptrend = .016).

269 Daily doses ranged from 20 mg to 60 mg for citalopram (m

270 ively breastfed infants received <20% of the daily dose recommended by the Institute of Medicine for

271 verse effects or switch to the use of a once-daily dosing regimen due to compliance issues.

272 he concentration-dependent activity and once-daily dosing regimen of telavancin.

273 After a daily dosing regimen, a shift to excitatory-inhibitory b

274 short half-life, necessitating a three times daily dosing regimen.

275 or antagonist, at the highest of three twice-daily dose regimens that the patient found tolerable, or

276 or in patients receiving once-daily vs twice-daily dosing regimens.

277 t of patients started at a 120 mg continuous daily dosing schedule, different from the standard inter

278 opment possess the promise of once- or twice-daily dosing schedules, improved tolerance profiles, hig

279 intermittent dosing and five (20%) receiving daily dosing; SD duration was 1.9-7.2 months (median 3.2

280 atients continued filling prescriptions with daily doses similar to chronic opioid users ( P = .05),

281 an immunodeficiency virus (HIV) include once-daily dosing, simplification of co-treatment for tubercu

282 of BCR-ABL signaling activity following once-daily dosing suggested acute, potent inhibition of kinas

283 time, but adherence decreased less with once-daily dosing than with twice-daily dosing.

284 t attainment rates for FDA- and EMA-approved daily doses to achieve colistin Css,avg of >/=0.5, >/=1,

285 Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profil

286 The median daily dose was 660 mg (IQR 389.2-800.0) sorafenib versus

287 The median daptomycin daily dose was 8.3 mg/kg (range, 6.4-10.7).

288 remained in CR, and 20% were in PR after the daily dose was reduced by 50%.

289 Mean TAC trough level (Cmin), used to adjust daily dose, was not different between the 2 groups in al

290 Median duration of treatment and mean daily dose were 12.5 months (IQR 2.6-35.8) and 577 mg pe

291 hloroquine toxicity, but height, weight, and daily dose were commonly not checked.

292 estimate because patient height, weight, and daily dose were not determined in 77 (35.1%), 84 (38.4%)

293 Mean daily doses were 4.2 mg (SD 0.6) for cariprazine and 3.8

294 Dasatinib 60 mg/m(2) and 80 mg/m(2) once-daily dosing were selected for phase II studies in child

295 renia were randomly assigned to receive once-daily dosing with 10 mg of ABT-126, 25 mg of ABT-126, or

296 Mice received once-daily dosing with amifostine (10-100 mg/kg, intraperiton

297 tudy provides preliminary evidence that once-daily dosing with dasotraline, a long-acting, dual monoa

298 The PK profile was supportive of once-daily dosing with median peak plasma concentrations at 1

299 e was escalated to 7,000 mg per day in twice-daily dosing with no DLTs; however, plasma lapatinib con

300 ) a study giving three 60-mg Fe doses (twice-daily dosing) within 24 hours (study 3, n = 13).